Alpha 1 proteinase inhibitor
Products billed under this code include Aralast NP, Prolastin-C, Zemaira.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Aralast NP, Prolastin-C, Zemaira.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Aralast NP | Takeda Pharmaceuticals America, Inc. | 00944-2814-01 | 0.1 | $0.5077 |
| Aralast NP | Takeda Pharmaceuticals America, Inc. | 00944-2815-01 | 0.1 | $0.5077 |
| Prolastin-C | Grifols USA, LLC | 13533-0705-01 | 0.1 | $0.5077 |
| Zemaira | CSL Behring L.L.C. | 00053-7201-02 | 0.1 | $0.5077 |
| Zemaira | CSL Behring L.L.C. | 00053-7202-02 | 0.1 | $0.5077 |
| Zemaira | CSL Behring L.L.C. | 00053-7203-02 | 0.1 | $0.5077 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.077 | −$0.056 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted September 17, 2026 |
| 3Q26 | $5.133 | −$0.008 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted September 15, 2026 |
| 2Q26 | $5.141 | −$0.231 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted September 15, 2026 |
| 1Q26 | $5.372 | −$0.085 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted September 15, 2026 |
| 4Q25 | $5.457 | +$0.272 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted September 8, 2026 |
| 3Q25 | $5.185 | +$0.025 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted March 10, 2026 |
| 2Q25 | $5.16 | +$0.069 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted March 10, 2026 |
| 1Q25 | $5.091 | +$0.156 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted December 19, 2025 |
| 4Q24 | $4.935 | +$0.104 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 11, 2025 |
| 3Q24 | $4.831 | −$0.081 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 11, 2025 |
| 2Q24 | $4.912 | +$0.029 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted March 11, 2025 |
| 1Q24 | $4.883 | +$0.077 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted December 19, 2024 |
| 4Q23 | $4.806 | −$0.072 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted October 10, 2024 |
| 3Q23 | $4.878 | +$0.102 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 5, 2024 |
| 2Q23 | $4.776 | +$0.184 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted February 23, 2024 |
| 1Q23 | $4.592 | +$0.022 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted December 6, 2023 |
| 4Q22 | $4.57 | −$0.043 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 22, 2023 |
| 3Q22 | $4.613 | +$0.078 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 9, 2023 |
| 2Q22 | $4.535 | −$0.011 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted December 14, 2022 |
| 1Q22 | $4.546 | +$0.007 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 8, 2022 |
| 4Q21 | $4.539 | −$0.024 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 2, 2022 |
| 3Q21 | $4.563 | +$0.052 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted June 2, 2022 |
| 2Q21 | $4.511 | −$0.012 | 10 MG | Alpha 1 proteinase inhibitor | v1, posted March 1, 2022 |
| 1Q21 | $4.523 | – | 10 MG | Alpha 1 proteinase inhibitor | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.